Quince Therapeutics Inc (NAS:QNCX)
$ 1.93 0.18 (10.29%) Market Cap: 84.92 Mil Enterprise Value: 44.61 Mil PE Ratio: 0 PB Ratio: 1.86 GF Score: 37/100

Cortexyme Inc at Canaccord Genuity Growth Conference (Virtual) Transcript

Aug 11, 2021 / 07:00PM GMT
Release Date Price: $110.65 (-7.95%)
Sumant Kulkarni
Canaccord Genuity - Analyst

Good day, everyone. I am Sumant Kulkarni, a senior biotechnology analyst here at Canaccord Genuity. And it's my pleasure to have Cortexyme with us presenting at our growth conference this year. Still in virtual format; hopefully it will be in person next year. From Cortexyme we have a multitasker, CFO and COO Chris Lowe.

We'll keep this very interactive, just day Q&A type session. If you have any questions, please feel free to send them across to me using your webpage interface, or you can email them to me at [email protected]. I'll turn it over to Chris to make a few remarks and then we'll go straight to the fireside component. Although fireside at 90° is not really the best way to go.

Chris Lowe
Cortexyme, Inc. - COO & CFO

Thanks, Sumant. It's great to be here. Clearly we are very excited about the evidence that our Company continues to build, deliver and be transparent about. And we think that's at the forefront of really the foundation of this Company to really shift the paradigm in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot